Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

Author: Benzinga Newsdesk | July 25, 2024 01:47am
  • Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment
  • Topline results for both UC and CD now anticipated in Q4 2024
  • Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug (anti-TL1A) for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) patients

Posted In: SNY TEVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist